Viridian Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for VRDN, updated each market day.
VRDN AI Sentiment
AI sees no strong directional signal for Viridian Therapeutics, Inc. Common Stock stock over the next 10 market days.
Prediction date: Sept. 17, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About Viridian Therapeutics, Inc. Common Stock
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
Sector
Exchange
Market Cap
$2,484,499,459
Cap Tier
Employees
252
Headquarters
WALTHAM, MA
Listed Since
June 18, 2014
VRDN Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
VRDN Volatility
Viridian Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings: this can present both opportunity and risk for traders.
